Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05159934 · ClinicalTrials.gov registry record · Phase 1
Nicotine Differences in Smokers
A Phase 1 study of Nicotine Dependence, sponsored by Yale University.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
- 1
- Study location
NCT05159934: Completed Phase 1 study of Nicotine Dependence, sponsored by Yale University.
NCT05159934 is a Phase 1 study of Nicotine Dependence that has completed, run by Yale University. The registered enrollment target is 11 participants, below the 187-participant average among 67 other Nicotine Dependence trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05159934, a Phase 1 study of Nicotine Dependence, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary aim of this project is to determine the threshold dose of nicotine, which the smokers will be able to differentiate from placebo (saline). Will use IV pulsed-nicotine infusion that closely matches nicotine delivery by inhaled tobacco use (i.e., tobacco cigarette or electronic cigarette), allowing precise and reproducible nicotine delivery. Four nicotine doses (0.1, 0.05, 0.025, and 0.0125 mg nicotine/pulse) which are within the range of nicotine doses that are delivered by cigarettes with very low to regular nicotine content. These doses will be delivered as a cluster of 4 pulsed-nicotine infusions of 2 sec duration with a 28 sec interval between each dose.
Primary Outcome
Liking effect
Conditions Studied
Interventions
- DRUG Saline
- DRUG 0.05, 0.025, and 0.0125 mg nicotine/pulse of nicotine
Study Locations (1)
Connecticut
- Veterans Affairs Hospital - West Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2022-02-16 |
| Est. Completion | 2023-08-01 |
| Phase | Phase 1 |
What the finished NCT05159934 record still lists
NCT05159934 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 187-participant average among 67 other Nicotine Dependence trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Nicotine Dependence appearing as the primary indexed condition, and to 2 interventions - of which Saline is the first listed.
NCT05159934 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT05159934 about?
NCT05159934 is a clinical study titled "Nicotine Differences in Smokers". The primary aim of this project is to determine the threshold dose of nicotine, which the smokers will be able to differentiate from placebo (saline). Will use IV pulsed-nicotine infusion that closely matches nicotine delivery by inhaled tobacco use (i.e., tobacco cigarette or electronic cigarette),...
What is the current status of trial NCT05159934?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2022-02-16. Estimated completion is 2023-08-01.
What conditions does trial NCT05159934 study?
This clinical trial studies the following conditions: Nicotine Dependence.
What interventions are being tested in trial NCT05159934?
The interventions under investigation include: Saline (DRUG), 0.05, 0.025, and 0.0125 mg nicotine/pulse of nicotine (DRUG).
Who is sponsoring clinical trial NCT05159934?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05159934 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nicotine Dependence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05159934's enrollment target sits among peer trials
11 66th of 67 higher than 2 of 67 other Nicotine Dependence trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Nicotine Dependence trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effects of Cannabidiol on Stress and Nicotine Withdrawal
RECRUITING · Phase 1
-
Overcoming Nicotine Dependence to Enable Quitting
RECRUITING · Phase 1
-
Comparative Pharmacokinetics and Pharmacodynamics of Synthetic Nicotine
RECRUITING · Phase 1
-
Brain Reaction to Treatment of Nicotine Dependence
COMPLETED · Phase 1
-
Effects of Nicotine on Elements of Attentions in Smokers and Nonsmokers
COMPLETED · Phase 1
-
New Approaches to Smoking Cessation in Heavy Drinkers
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI